Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 24.6% in March

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 4,610,000 shares, an increase of 24.6% from the February 28th total of 3,700,000 shares. Based on an average daily volume of 1,440,000 shares, the days-to-cover ratio is presently 3.2 days. Approximately 5.7% of the company’s stock are sold short.

Analyst Ratings Changes

CMPX has been the topic of a number of recent research reports. Guggenheim reiterated a “buy” rating and set a $12.00 price objective on shares of Compass Therapeutics in a research note on Wednesday. Jefferies Financial Group raised their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. Leerink Partners raised shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $4.00 to $6.00 in a report on Wednesday. D. Boral Capital reissued a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a report on Tuesday. Finally, Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research report on Tuesday. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.63.

Compass Therapeutics Trading Down 24.6 %

Shares of CMPX opened at $1.69 on Thursday. The firm has a market cap of $233.70 million, a P/E ratio of -4.57 and a beta of 1.19. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $4.08. The stock’s 50 day moving average is $2.81 and its two-hundred day moving average is $2.11.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Equities research analysts forecast that Compass Therapeutics will post -0.36 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Barclays PLC increased its stake in Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after buying an additional 112,614 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after acquiring an additional 356,352 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Compass Therapeutics by 0.8% during the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after purchasing an additional 19,095 shares in the last quarter. Bleakley Financial Group LLC raised its stake in Compass Therapeutics by 250.7% in the 4th quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock valued at $58,000 after purchasing an additional 28,589 shares during the last quarter. Finally, Intech Investment Management LLC lifted its holdings in Compass Therapeutics by 218.7% in the 4th quarter. Intech Investment Management LLC now owns 51,924 shares of the company’s stock valued at $75,000 after purchasing an additional 35,632 shares in the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.